Executive Vice President Jeong Jae-uk Acquires 250 Shares of GC Biopharma via Open Market Purchase, Signaling Management Confidence

Registered executive Jeong Jae-uk, Vice President of GC Biopharma, purchased an additional 250 common shares at 121,348 KRW per share through open market transactions on June 15, 2026, raising his total holdings to 500 shares.
The acquisition is interpreted as a personal investment or a signal of management confidence, but the small volume has limited direct impact on the stock price.
[AI Summary]The minor insider buying by a GC Biopharma executive demonstrates management commitment, but the negligible proportion relative to total shares outstanding does not materially affect stock valuation. Investors should monitor for larger capital allocation moves or fundamental changes.